Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
about
Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporterNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesSigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neuronsGlutamate in neurologic diseasesMetabotropic glutamate receptors in the basal ganglia motor circuitMetabolic consequences of the cytochrome c oxidase deficiency in brain of copper-deficient Mo(vbr) mice1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism.Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes.Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.Protective effect of ultra low molecular weight heparin on glutamate-induced apoptosis in cortical cellsEtiology of Parkinson's disease.AMP kinase-mediated activation of the BH3-only protein Bim couples energy depletion to stress-induced apoptosis.NMDA receptors in the basal ganglia.Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease.Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra.Neuroprotective potential of ionotropic glutamate receptor antagonists.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesEstrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Are human neurodegenerative disorders linked to environmental chemicals with excitotoxic properties?Neurotoxin-related research: from the laboratory to the clinic.The development of mitochondrial medicine.The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention.New therapeutic approaches to Parkinson's disease including neural transplants.Antioxidative therapeutic strategies for Parkinson's disease.Features of the dopaminergic neurotoxin MPTP.Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging.Interleukin-1beta: a bridge between inflammation and excitotoxicity?N-methyl-D-aspartate receptor-mediated neuroprotection in cerebellar granule cells requires new RNA and protein synthesis.N-Methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain.Ampelopsis Radix Protects Dopaminergic Neurons against 1-Methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Toxicity in Parkinson's Disease Models In Vitro and In Vivo.Targets for neuroprotection in Parkinson's disease2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin.Glutamate receptors as therapeutic targets for Parkinson's disease.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.MPTP mouse models of Parkinson's disease: an update.A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.
P2860
Q24552403-04EFA03D-8027-4460-B76C-C265D6329F33Q26747508-A1C59E34-682B-47EA-9E56-9E0C748C3FE2Q27330088-C849E98E-2760-4A2B-8019-7282C16360C6Q28259105-9BF32167-88CB-4F8E-9BC6-18734C395AAFQ28280931-8044ECBF-F187-455C-BBE7-6DE8A0A2BC4FQ28507748-CB4001E6-72D8-4E09-A327-96FE86D68CFEQ30978603-200A78E4-BC7A-462A-A8D6-0AA0776C80B5Q31913332-EAEF4B58-3D3B-4B96-A4F1-60A7B4739623Q32034638-6D2CC134-B66C-468F-B084-0F726C7BD29AQ33183865-217801FF-5340-4984-B7B6-D5F0DB636C10Q33191656-E7394612-E03B-41B7-B428-25BF59E32B45Q33346851-74E9701F-66EA-47BD-AE91-0FC6D064E5E3Q33714108-2FB8FC9D-9078-4356-81ED-71823F34CA2DQ33788455-AF82C65A-A0F2-4AEC-95C5-17E48AAD957DQ33989361-C31F13F6-59DA-45E5-B15E-C1E5C90136F0Q34095853-7E5FCBF6-D649-4536-B224-D5D4E9F98095Q34169019-98B5BEB5-8802-4990-8072-06B65C29DBF9Q34209297-83C14359-5F25-404F-BEE3-C2A8ADFFCAB9Q34329204-2AA1D287-0314-4587-8B37-4CD7EF9D6350Q34784469-49AE010D-937F-4E45-A355-78562EFC8802Q35065682-0B5615C1-2BA0-49DB-900D-AD0182AB67F5Q35230778-03A79775-2A21-41E6-82B0-544FA674BAF3Q35260764-E1855CB3-5D23-4A42-B7EB-8201C6AFC74FQ35744478-1EDE0667-6046-4BA3-97A3-8CDA4FA15C24Q36137988-70013CF7-FCCD-4711-8EF4-CA288FD4E306Q36225073-1E5F2D6F-C6EC-4ADD-8C69-1AAE3AC87643Q36349448-1F8F1717-9226-49E3-BE3A-3E5B443683C0Q36349469-1DA02177-7650-4AD7-9471-3D3DC865CF94Q36798056-1BDC9F26-9DAF-4625-B27F-BBC1546E60CDQ37100241-8534628A-3C0E-4397-9F74-D06715222DFDQ37111818-4EF6185B-2B14-4517-9F2A-E2A024A437D2Q37190678-217C5B93-5265-4F6F-9F77-2A6E540501F9Q37239705-14E9C122-CB76-4E34-84F7-B3237F93506BQ37302453-2F372E3B-81DF-42DB-B443-A9BB102C00F7Q37525043-FA55E1F6-F394-4ADA-ACA2-372A48268BD0Q37585401-2D19118F-A89D-490C-8390-5A64444D55CEQ37741285-DA886D3E-D381-4AE3-BC25-DAF508B49887Q38056852-29054E06-B734-4866-8D2D-1AF017FAD390Q38070400-C12E3ACD-840F-4784-A42A-280BAEA4D8E9Q38174986-3338A7F6-0D30-43A4-8762-E1A8027F0E75
P2860
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Protection of substantia nigra ...... ethyl-D-aspartate antagonists.
@en
type
label
Protection of substantia nigra ...... ethyl-D-aspartate antagonists.
@en
prefLabel
Protection of substantia nigra ...... ethyl-D-aspartate antagonists.
@en
P2093
P356
P1433
P1476
Protection of substantia nigra ...... ethyl-D-aspartate antagonists.
@en
P2093
P2888
P304
P356
10.1038/349414A0
P407
P577
1991-01-01T00:00:00Z
P6179
1005980055